Trial Profile
Cost-Effectiveness of Prophylaxis with Anti-Inhibitor Complex Concentrate in Patients with Hemophilia A and Inhibitors: the Pro-FEIBA Study
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Sep 2015
Price :
$35
*
At a glance
- Drugs Factor VIII inhibitor bypassing fraction (Primary)
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms PRO-FEIBA
- 07 Nov 2012 Results of a quality-of-life analysis presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
- 07 Nov 2012 Results of a cost-effectiveness analysis presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.
- 21 Dec 2011 New trial record